OR WAIT null SECS
June 18, 2024
Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.
The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.
May 30, 2024
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.
Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.
May 24, 2024
With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.
May 22, 2024
The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.